Clinical trials
Stem Cell clinical trials
Below are recruiting stem cell clinical trials, each written for real people, not researchers. We’re tracking 741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05018858RecruitingPhase 1
Test stem cell infusion safety for lupus
This early-phase study tests whether an intravenous (through a vein) stem cell treatment made from donated umbilical cord tissue is safe for people with lupus. It focuses mainly on side effects and how well participants tolerate the infusion.
St John'sAges Any age - NCT05088226RecruitingPhase 2
Ruxolitinib plus chidamide before transplant for high-risk leukemia
This Phase 2 study tests whether adding two medicines (ruxolitinib and chidamide) to a “conditioning regimen” before an allogeneic stem cell transplant improves outcomes for people with high-risk B-cell ALL. It may help prepare the body for transplant and reduce the chance of leukemia coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT05224960RecruitingPhase 2
Stem cell treatment for worsening liver cirrhosis
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
Lanzhou, GansuAges 18–75 - NCT05319353RecruitingPhase 3
Maribavir for kids with CMV after transplant
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Wilmington, DelawareAges Up to 17 years - NCT05086003RecruitingPhase 2
Kidney transplant with stem cell treatment to build immune tolerance
This Phase 2 study tests a combined treatment—kidney transplant plus stem cell–based immune therapy—to help the body accept the new kidney with less immune attack. You may be able to take part if you have a matching sibling donor and meet key safety and health requirements.
Petah TikvaAges 18–65 - NCT05421416RecruitingPhase 2
Loratadine to prevent bone pain after stem cell transplant treatment
This trial tests loratadine (an allergy medicine) to see if it can prevent bone pain caused by a growth-factor injection used during lymphoma or multiple myeloma treatment. It may help reduce pain around the time you get that injection and your upcoming stem cell transplant.
Edmonton, AlbertaAges 18 years+ - NCT04517656Recruiting
Testing blood markers after a bone marrow donor transplant
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Saint-EtienneAges 18 years+ - NCT04099082Recruiting
Predicting lung scarring after a specific viral infection
This study looks at how your immune response to a particular virus (PIV) might predict future lung scarring called bronchiolitis obliterans. It may help doctors better identify who is at higher risk after a stem cell transplant.
Paris, Île-de-France RegionAges 18 years+ - NCT03850418RecruitingPhase 2
Azacitidine for blood chimerism changes after transplant
This Phase 2 study tests whether azacitidine can improve outcomes when donor blood “chimerism” starts dropping after an allogeneic stem cell transplant. It’s for people with AML, MDS, MPN, or CMML who are experiencing early warning signs in their blood counts after transplant but without clear relapse in the bone marrow.
Detroit, MichiganAges 18–75 - NCT04061239RecruitingPhase 2
New treatment options before stem cell transplant for higher-risk MDS/AML
This Phase 2 trial compares treatment approaches for people with higher-risk MDS or a specific type of AML before they get a stem cell transplant. The goal is to see which approach helps you get ready for transplant more safely and effectively.
LinzAges 18–75 - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35 - NCT05851105RecruitingEarly Phase 1
Study drug for severe alpha thalassemia in people needing regular transfusions
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
Nanning, GuangxiAges 12–35 - NCT04476901RecruitingPhase 2
Study of donor stem cell treatment for non-ischemic heart failure
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
Stanford, CaliforniaAges 18–80 - NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT07693881Recruiting
Preventing EBV reactivation with rituximab after stem cell transplant in children
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
GuangzhouAges Up to 18 years - NCT05018767RecruitingPhase 1
Testing an IV stem cell treatment for aging frailty safety
This early study (Phase 1) tests whether a lab-made stem cell product given through an IV is safe in people with “aging frailty.” It looks mainly at side effects and safety while also exploring whether the treatment can be given safely.
St John'sAges Any age - NCT07214688RecruitingPhase 2
Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Washington D.C., District of ColumbiaAges 18–65 - NCT05773729Recruiting
Gene-modified own stem cell treatment for transfusion-dependent thalassemia
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
ShanghaiAges 3–18 - NCT07047183RecruitingPhase 2
A study of venetoclax and azacitidine before stem cell transplant for MDS
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
Changchun, JilinAges 18 years+ - NCT06083129RecruitingPhase 3
Preventing GVHD after stem cell transplant in older adults
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
AmiensAges 50–70 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07101588RecruitingPhase 4
Ruxolitinib and decitabine before stem cell transplant for AML
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
Beijing, Beijing MunicipalityAges 14–75 - NCT06743477Recruiting
Super transplant for severe thalassemia in children
This trial tests a new type of transplant (called 'super transplantation') for children with severe thalassemia. It aims to help those who cannot get a fully matched donor or have chosen not to have standard treatments.
Kunming, YunnanAges 7–12 - NCT06075563Recruiting
Total Lymphoid Irradiation for Children's Stem Cell Transplant
This trial tests a special type of radiation (total lymphoid irradiation) as part of the preparation for a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for children who need a transplant but don't have a fully matched sibling donor.
Hong KongAges Up to 18 years
Hear when a new Stem Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stem cell?
- Yes. Clin2 currently lists 741 recruiting stem cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stem cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stem cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.